T1	Condition 256 271	mitral stenosis
T2	Condition-Name 256 271	mitral stenosis
E1	Condition:T1 Name:T2 Severity:T33
T3	Procedure 391 406	anticoagulation
T4	Procedure-Name 391 406	anticoagulation
E3	Procedure:T3 Name:T4 Temporality:E21
T5	Procedure 126 136	procedures
T6	Procedure-Name 126 136	procedures
E5	Procedure:T5 Name:T6
T8	Condition 606 623	renal dysfunction
T9	Condition-Name 606 623	renal dysfunction
E8	Condition:T8 Name:T9 Severity:T53
T10	Procedure 484 499	oral medication
T11	Procedure-Name 484 499	oral medication
E10	Procedure:T10 Name:T11
T14	Eq-Operator 203 204	≥
A1	Eq-Operator-Value T14 GTEQ
T16	Eq-Operator 653 654	<
A3	Eq-Operator-Value T16 LT
T17	Eq-Temporal-Unit 370 376	months
A4	Eq-Temporal-Unit-Value T17 month
T18	Eq-Value 205 207	18
T19	Eq-Value 367 369	12
T20	Eq-Value 654 656	15
T21	Eq-Comparison 203 216	≥ 18 year-old
E13	Eq-Comparison:T21 Operator:T14 Value:T18 Temporal-Unit:T31
T22	Eq-Comparison 653 663	<15 mL/min
E14	Eq-Comparison:T22 Operator:T16 Value:T20 Unit:T58 Per:T59
T23	Eq-Comparison 283 290	history
E15	Eq-Comparison:T23 Temporal-Period:T24
T24	Eq-Temporal-Period 283 290	history
A5	Eq-Temporal-Period-Value T24 past
T25	Eq-Comparison 361 376	prior 12 months
E16	Eq-Comparison:T25 Temporal-Period:T26 Value:T19 Temporal-Unit:T17
T26	Eq-Temporal-Period 361 366	prior
A6	Eq-Temporal-Period-Value T26 past
T27	Study 120 125	study
E2	Study:T27 Study-Of:E5
T28	Assertion 89 100	willingness
E4	Assertion:T28 Asserted:E5
A7	Assertion-Type-Value E4 hypothetical
T7	Life-Stage-And-Gender 189 192	Men
A8	Life-Stage-And-Gender-Type T7 male
T29	Life-Stage-And-Gender 197 202	women
A9	Life-Stage-And-Gender-Type T29 female
T30	Or 193 196	and
E6	Or:T30 Arg:T7 Arg2:T29
T31	Eq-Temporal-Unit 208 212	year
A10	Eq-Temporal-Unit-Value T31 year
T32	Age 213 216	old
E7	Age:T32 Eq-Comparison:E13
T33	Severity 249 255	severe
A11	Severity-Value T33 severe
T34	Severity 237 245	moderate
A12	Severity-Value T34 moderate
T35	Eq-Comparison 237 255	moderate to severe
E9	Eq-Comparison:T35 Value:T34 Value2:T33 Operator:T36
T36	Eq-Operator 246 248	to
A13	Eq-Operator-Value T36 BETWEEN
T37	Condition 294 296	AF
E11	Condition:T37 Name:T38 Temporality:E15 Temporality2:E16
T38	Condition-Name 294 296	AF
T39	And 272 275	who
E17	And:T39 Arg:E1 Arg2:E11
T15	Procedure 331 349	electrical tracing
E18	Procedure:T15 Name:T40
T40	Procedure-Name 331 349	electrical tracing
R1	Found-By Arg1:E11 Arg2:E18	
T41	Indication 410 419	indicated
E19	Indication:T41 Indication-For:E3
T42	Study 456 461	study
E20	Study:T42 
T43	Eq-Comparison 424 435	planned for
E21	Eq-Comparison:T43 Temporal-Period:T44
T44	Eq-Temporal-Period 424 435	planned for
A2	Eq-Temporal-Period-Value T44 future
T45	Temporal-Connection 440 448	duration
E22	Temporal-Connection:T45 Arg:E21 Arg2:E20
A14	Temporal-Connection-Type-Value E22 during
T46	And 377 380	and
E23	And:T46 Arg:E11 Arg2:E3
T47	Assertion 468 478	Ability to
E24	Assertion:T47 Asserted:E10
A15	Assertion-Type-Value E24 hypothetical
T12	Drug 532 543	rivaroxaban
E12	Drug:T12 Name:T13
T13	Drug-Name 532 543	rivaroxaban
T48	Assertion 507 517	willing to
E25	Assertion:T48 Asserted:E12
A16	Assertion-Type-Value E25 hypothetical
T49	And 500 503	and
E26	And:T49 Arg:E24 Arg2:E25
T50	Modifier 577 588	Left atrial
E27	Modifier:T50 Modifies:T52
T51	Condition 589 593	clot
E28	Condition:T51 Name:T52
T52	Condition-Name 589 593	clot
T53	Severity 599 605	Severe
A17	Severity-Value T53 severe
T54	Observation 625 645	creatinine clearance
E29	Observation:T54 Name:T55
T55	Observation-Name 625 645	creatinine clearance
A18	Observation-Type-Value T55 lab
T56	Observation 647 651	CrCl
E30	Observation:T56 Name:T57 Eq-Comparison:E14
T57	Observation-Name 647 651	CrCl
R2	Abbrev-Of Arg1:E30 Arg2:E29	
T58	Eq-Unit 657 659	mL
T59	Eq-Temporal-Unit 660 663	min
A19	Eq-Temporal-Unit-Value T59 minute
T60	Condition 687 696	condition
E31	Condition:T60 
T61	Condition 728 736	bleeding
E32	Condition:T61 Name:T62
T62	Condition-Name 728 736	bleeding
T63	Risk 720 724	risk
E33	Risk:T63 Risk-For:E32 Polarity:T64
T64	Polarity 715 719	high
A20	Polarity-Value T64 high
R3	Caused-By Arg1:E33 Arg2:E31	
T65	Allergy 742 750	Allergic
E34	Allergy:T65 Name:E35 Name2:E37
T66	Drug-Name 754 764	rivaroxabn
T67	Drug 754 764	rivaroxabn
E35	Drug:T67 Name:T66
T68	Or 764 765	/
E36	Or:T68 Arg:E35 Arg2:E37
T69	Drug 765 773	warfarin
E37	Drug:T69 Name:T70
T70	Drug-Name 765 773	warfarin
